Early clinical experience with subcutaneous GR43175 in acute migraine: an overview.
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.
Tfelt-Hansen
P
P
Department of Neurology, University Hospital, Gentofte, Denmark.
Brand
J
J
Dano
P
P
Doenicke
A
A
Findley
L J
LJ
Iversen
H K
HK
Melchart
D
D
Sahlender
H M
HM
D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018170:Sumatriptan
D007211:Indoles; D013449:Sulfonamides; D018170:Sumatriptan